Epithelial Neoplasms of the Large Intestine

Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas

Volumn , Issue , 2009, Pages 597-637

  Redston, Mark ^a  

^a AmeriPath Northeast   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882841304     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141604059-0.50026-6     Document Type: Chapter

References (271)

1. Pathology and Genetics of Tumours of the Digestive System 2000, 314. IARC Press, World Health Organization Classification of Tumours. Lyon, France. S.R. Hamilton, L.A. Aaltonen (Eds.).
2. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer. AJCC Cancer Staging Manual 2002, 435. Springer-Verlag, New York.
3. Honda T, Kai I, Ohi G Fat and dietary fiber intake and colon cancer mortality: A chronological comparison between Japan and the United States. Nutr Cancer 1999, 33:95-99.
4. American Cancer Society Cancer Facts and Figures 2008 2008, American Cancer Society, Atlanta.
5. Burt RW Colon cancer screening. Gastroenterology 2000, 119:837-853.
6. Thomas RM, Sobin LH Gastrointestinal cancer. Cancer 1995, 75(1 Suppl):154-170.
7. Garfinkel L, Mushinski M U.S. cancer incidence, mortality and survival: 1973-1996. Stat Bull Metrop Insur Co 1999, 80(3):23-32.
8. Allam MF, Lucena RA Aetiology of sex differences in colorectal cancer. Eur J Cancer Prev 2001, 10:299-300.
9. Truswell AS Meat consumption and cancer of the large bowel. Eur J Clin Nutr 2002, 56(Suppl 1):S19-S24.
10. Bruce WR, Giacca A, Medline A Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2000, 9:1271-1279.
11. Sandhu MS, Dunger DB, Giovannucci EL Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002, 94:972-980.
12. Kim YI Vegetables, fruits, and colorectal cancer risk: What should we believe?. Nutr Rev 2001, 59:394-398.
13. Hill MJ Vegetables, fruits, fibre and colorectal cancer. Eur J Cancer Prev 2002, 11:1-2.
14. Giovannucci E Epidemiologic studies of folate and colorectal neoplasia: A review. J Nutr 2002, 132(8 Suppl):2350s-2355s.
15. Seitz HK, Matsuzaki S, Yokoyama A, et al. Alcohol and cancer. Alcohol Clin Exp Res 2001, 25(5 Suppl ISBRA):137s-143s.
16. Chan TA Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002, 3:166-174.
17. Giovannucci E An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:725-731.
18. Boyle P, Langman JS ABC of colorectal cancer: Epidemiology. BMJ 2000, 321:805-808.
19. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from three centres. Gut 1988, 29:206-217.
20. Tsunoda A, Shibusawa M, Kawamura M, et al. Colorectal cancer after pelvic irradiation: Case reports. Anticancer Res 1997, 17:729-732.
21. Iacopetta B Are there two sides to colorectal cancer?. Int J Cancer 2002, 101:403-408.
22. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000, 284:1954-1961.
23. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy: The National Polyp Study Workgroup. N Engl J Med 1993, 329:1977-1981.
24. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001-testing for early lung cancer detection. CA Cancer J Clin 2001, 51:38-75. quiz 77-80.
25. Stack E, Dubois RN Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 2001, 30:1001-1010.
26. Gwyn K, Sinicrope FA Chemoprevention of colorectal cancer. Am J Gastroenterol 2002, 97:13-21.
27. Kim EC, Lance P Colorectal polyps and their relationship to cancer. Gastroenterol Clin North Am 1997, 26:1-17.
28. Fenoglio-Preiser CM, Pascal RR, Perzin KH Tumors of the Intestines. Atlas of Tumor Pathology. Second Series, Fascicle 27 1990, Armed Forces Institute of Pathology, Washington, DC.
29. Roncucci L, Pedroni M, Vaccina F, et al. Aberrant crypt foci in colorectal carcinogenesis: Cell and crypt dynamics. Cell Prolif 2000, 33:1-18.
30. Takayama T, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998, 339:1277-1284.
31. Mueller JD, Bethke B, Stolte M Colorectal de novo carcinoma: A review of its diagnosis, histopathology, molecular biology, and clinical relevance. Virchows Arch 2002, 440:453-460.
32. Hornick JL, Farraye FA, Odze RD Clinicopathologic and immunohistochemical study of small, apparently "de novo" colorectal adenocarcinomas. Am J Surg Pathol 2007, 31:207-215.
33. The Molecular Basis of Cancer 2001, 691. WB Saunders, Philadelphia. 2nd ed. J. Mendelsohn, P.M. Howley, M.A. Israel, L.A. Liotta (Eds.).
34. The Genetic Basis of Human Cancer 1998, 731. McGraw-Hill, New York. B. Vogelstein, K.W. Kinzler (Eds.).
35. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
36. Kinzler KW, Vogelstein B Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
37. Fearon ER, Vogelstein B A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
38. Loeb LA Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991, 51:3075-3079.
39. Lengauer C, Kinzler KW, Vogelstein B DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci U S A 1997, 94:2545-2550.
40. Lengauer C, Kinzler KW, Vogelstein B Genetic instabilities in human cancers. Nature 1998, 396:643-649.
41. Kinzler KW, Vogelstein B Cancer-susceptibility genes: Gatekeepers and caretakers. Nature 1997, 386(761):763.
42. Jass JR, Whitehall VL, Young J, Leggett BA Emerging concepts in colorectal neoplasia. Gastroenterology 2002, 123:862-876.
43. Jubb AM, Bell SM, Quirke P Methylation and colorectal cancer. J Pathol 2001, 195:111-134.
44. Rountree MR, Bachman KE, Herman JG, Baylin SB DNA methylation, chromatin inheritance, and cancer. Oncogene 2001, 20:3156-3165.
45. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999, 96:8681-8686.
46. Jass JR Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
47. Fodde R The APC gene in colorectal cancer. Eur J Cancer 2002, 38:867-871.
48. Moon RT, Bowerman B, Boutros M, Perrimon N The promise and perils of Wnt signaling through beta-catenin. Science 2002, 296:1644-1646.
49. Leslie A, Carey FA, Pratt NR, Steele RJ The colorectal adenoma-carcinoma sequence. Br J Surg 2002, 89:845-860.
50. Hawkins NJ, Ward RL Sporadic colorectal cancers with mi-crosatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 2001, 93:1307-1313.
51. Iino H, Jass JR, Simms LA, et al. DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: A mild mutator pathway for colorectal cancer?. J Clin Pathol 1999, 52:5-9.
52. Odze RD, Brien T, Brown CA, et al. Molecular alterations in chronic ulcerative colitis-associated and sporadic hyperplastic polyps: A comparative analysis. Am J Gastroenterol 2002, 97:1235-1242.
53. Young J, Jass JR The case for a genetic predisposition to serrated neoplasia in the colorectum: Hypothesis and review of the literature. Cancer Epidemiol Biomarkers Prev 2006, 15:1778-1784.
54. Young J, Jenkins M, Parry S, et al. Serrated pathway colorectal cancer in the population: Genetic consideration. Gut 2007, 56:1453-1459.
55. Makinen MJ Colorectal serrated adenocarcinoma. Histopathology 2007, 50:131-150.
56. Henson DE, Hutter RVP, Sobin LH, Bowman HE Protocol for the examination of specimens removed from patients with colorectal carcinoma: A basis for checklists. Cancer Committee, College of American Pathologists. Task Force for Protocols on the Examination of Specimens from Patients with Colorectal Cancer. Arch Pathol Lab Med 1994, 118:122-125.
57. Compton CC Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: A basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000, 124:1016-1025.
58. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000, 124:979-994.
59. Yamamoto S, Mochizuki H, Hase K, et al. Assessment of clinicopathologic features of colorectal mucinous adenocarcinoma. Am J Surg 1993, 166:257-261.
60. Lewin KJ, Riddell RH, Weinstein WM Gastrointestinal Pathology and Its Clinical Implications 1992, Igaku-Shoin, New York.
61. Hermanek P, Sobin LH Colorectal carcinoma. Prognostic Factors in Cancer 1995, 64-921. Springer-Verlag, New York. P. Hermanek, M.K. Gospodarowicz, D.E. Henson (Eds.).
62. Hermanek P, Guggenmoos-Holzmann I, Gall FP Prognostic factors in rectal carcinoma: A contribution to the further development of tumor classification. Dis Colon Rectum 1989, 32:593-599.
63. Blenkinsopp WK, Stewart-Brown S, Blesovsky L, et al. Histopathology reporting in large bowel cancer. J Clin Pathol 1981, 34:509-513.
64. Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: Historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986, 10:437-459.
65. Compton CC Pathology report in colon cancer: What is prognostically important?. Dig Dis 1999, 17:67-79.
66. Jass JR, O'Brien MJ, Riddell RH, Snover DC, et al. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 2007, 38:537-545.
67. Symonds DA, Vickery AL Mucinous carcinoma of the colon and rectum. Cancer 1976, 37:1891-1900.
68. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001, 158:527-535.
69. Messerini L, Vitelli F, De Vitis LR, et al. Microsatellite instability in sporadic mucinous colorectal carcinomas: Relationship to clinico-pathological variables. J Pathol 1997, 182:380-384.
70. Park ET, Oh HK, Gum JR, et al. HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res 2006, 12:5403-5410.
71. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002, 45:200-206.
72. Connelly JH, Robey-Cafferty SS, Cleary KR Mucinous carcinomas of the colon and rectum: An analysis of 62 stage B and C lesions. Arch Pathol Lab Med 1991, 115:1022-1025.
73. Consorti F, Lorenzotti A, Midiri G, Di Paola M Prognostic significance of mucinous carcinoma of colon and rectum: A prospective case-control study. J Surg Oncol 2000, 73:70-74.
74. Umpleby HC, Ranson DL, Williamson RC Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985, 72:715-718.
75. Anthony T, George R, Rodriguez-Bigas M, Petrelli NJ Primary signet-ring cell carcinoma of the colon and rectum. Ann Surg Oncol 1996, 3:344-348.
76. Messerini L, Palomba A, Zampi G Primary signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum 1995, 38:1189-1192.
77. Psathakis D, Schiedeck TH, Krug F, et al. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: Study matched for age, gender, grade, and stage. Dis Colon Rectum 1999, 42:1618-1625.
78. Tung SY, Wu CS, Chen PC Primary signet ring cell carcinoma of colorectum: An age- and sex-matched controlled study. Am J Gastroenterol 1996, 91:2195-2199.
79. Ojeda VJ, Mitchell KM, Walters MN-I, Gibson MJ Primary colo-rectal linitis plastica type of carcinoma: Report of two cases and review of the literature. Pathology 1982, 14:181-189.
80. Hayashi H, Kitamura H, Nakatani Y, et al. Primary signet-ring cell carcinoma of the lung: Histochemical and immunohistochemical characterization. Hum Pathol 1999, 30:378-383.
81. Makino T, Tsujinaka T, Mishima H, et al. Primary signet-ring cell carcinoma of the colon and rectum: Report of eight cases and review of 154 Japanese cases. Hepatogastroenterology 2006, 53:845-849.
82. Nakahara H, Ishikawa T, Itabashi M, Hirota T Diffusely infiltrating primary colorectal carcinoma of linitis plastica and lymphangiosis types. Cancer 1992, 69:901-906.
83. Shirouzu K, Isomoto H, Morodomi T, et al. Primary linitis plastica carcinoma of the colon and rectum. Cancer 1994, 74:1863-1868.
84. Jessurun J, Romero-Guadarrama M, Manivel JC Medullary adenocarcinoma of the colon: Clinicopathologic study of 11 cases. Hum Pathol 1999, 30:843-848.
85. Hinoi T, Tani M, Lucas PC, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol 2001, 159:2239-2248.
86. Wick MR, Vitsky JL, Ritter JH, et al. Sporadic medullary carcinoma of the colon: A clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol 2005, 123:56-65.
87. Frizelle FA, Hobday KS, Batts KP, Nelson H Adenosquamous and squamous carcinoma of the colon and upper rectum: A clinical and histopathologic study. Dis Colon Rectum 2001, 44:341-346.
88. Cagir B, Nagy NW, Topham A, et al. Adenosquamous carcinoma of the colon, rectum, and anus: Epidemiology, distribution, and survival characteristics. Dis Colon Rectum 1999, 42:258-263.
89. Petrelli NJ, Valle AA, Weber TK, Rodriguez-Bigas M Adenosquamous carcinoma of the colon and rectum. Dis Colon Rectum 1996, 39:1265-1268.
90. Thompson JT, Paschold EH, Levine EA Paraneoplastic hypercalcemia in a patient with adenosquamous cancer of the colon. Am Surg 2001, 67:585-588.
91. Fukui R, Hata F, Yasoshima T, et al. Adenosquamous carcinoma of the colorectum: Report of two cases. J Exp Clin Cancer Res 2001, 20:293-296.
92. Lafreniere R, Ketcham AS Primary squamous carcinoma of the rectum: Report of a case and review of the literature. Dis Colon Rectum 1985, 28:967-972.
93. Anagnostopoulos G, Sakorafas GH, Kostopoulos P, et al. Squamous cell carcinoma of the rectum: A case report and review of the literature. Eur J Cancer Care 2005, 14:70-74.
94. Audeau A, Han HW, Johnston MJ, et al. Does human papilloma virus have a role in squamous cell carcinoma of the colon and upper rectum?. Eur J Surg Oncol 2002, 28:657-660.
95. Sotlar K, Koveker G, Aepinus C, et al. Human papillomavirus type 16-associated primary squamous cell carcinoma of the rectum. Gastroenterology 2001, 120:988-994.
96. Weidner N, Zekan P Carcinosarcoma of the colon: Report of a unique case with light and immunohistochemical studies. Cancer 1986, 58:1126-1130.
97. Nakao A, Sakagami K, Uda M, et al. Carcinosarcoma of the colon: Report of a case and review of the literature. J Gastroenterol 1998, 33:276-279.
98. Di Vizio D, Insabato L, Conzo G, et al. Sarcomatoid carcinoma of the colon: A case report with literature review. Tumori 2001, 87:431-435.
99. Ambrosini-Spaltro A, Vaira V, Braidotti P, et al. Carcinosarcoma of the colon: Report of a case with morphological, ultrastructural and molecular analysis. BMC Cancer 2006, 6:185.
100. Isimbaldi G, Sironi M, Assi A Sarcomatoid carcinoma of the colon: Report of the second case with immunohistochemical study. Pathol Res Pract 1996, 192:483-487.
101. Aramendi T, Fernandez-Acenero MJ, Villanueva MC Carcinosarcoma of the colon: Report of a rare tumor. Pathol Res Pract 2003, 199:345-348.
102. Tokisue M, Yasutake K, Oya M, et al. Coexistence of choriocarcinoma and adenocarcinoma in the rectum: Molecular aspects. J Gastroenterol 1996, 31:431-436.
103. Ostor AG, McNaughton WM, Fortune DW, et al. Rectal adenocarcinoma with germ cell elements treated with chemotherapy. Pathology 1993, 25:243-246.
104. Metz KA, Richter HJ, Leder LD Adenocarcinoma of the colon with syncytiotrophoblastic differentiation: Differential diagnosis and implications. Pathol Res Pract 1985, 179:419-424.
105. Kiran RP, Visvanathan R, Simpson CG Choriocarcinomatous metaplasia of a metachronous adenocarcinoma of the colon. Eur J Surg Oncol 2001, 27:436-437.
106. Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 2004, 47:163-169.
107. Burke AB, Shekitka KM, Sobin LH Small cell carcinomas of the large intestine. Am J Clin Pathol 1991, 95:315-321.
108. Klappenbach RS, Kurman RJ, Sinclair CF, James LP Composite carcinoma-carcinoid tumors of the gastrointestinal tract: A morphologic, histochemical, and immunocytochemical study. Am J Clin Pathol 1985, 84:137-143.
109. Isaacson P Crypt cell carcinoma of the appendix (so-called adenocarcinoid tumor). Am J Surg Pathol 1981, 5:213-224.
110. Watson PH, Alguacil-Garcia A Mixed crypt cell carcinoma: A clinicopathological study of the so-called "goblet cell carcinoid. rdquo; Virchows Arch A Pathol Anat Histopathol 1987, 412:175-182.
111. Chumas JC, Lorelle CA Melanotic adenocarcinoma of the anorectum. Am J Surg Pathol 1981, 5:711-717.
112. Jewell LD, Barr JR, McCaughey WT, et al. Clear-cell epithelial neoplasms of the large intestine. Arch Pathol Lab Med 1988, 112:197-199.
113. Thibodeau SN, Bren G, Schaid D Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
114. Haydon AM, Jass JR Emerging pathways in colorectal-cancer development. Lancet Oncol 2002, 3:83-88.
115. Jass JR, Smyrk TC, Stewart SM, et al. Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res 1994, 14:1631-1634.
116. Jass JR HNPCC and sporadic MSI-H colorectal cancer: A review of the morphological similarities and differences. Fam Cancer 2004, 3:93-100.
117. Kim H, Jen J, Vogelstein B, Hamilton SR Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994, 145:148-156.
118. Ilyas M, Tomlinson IPM, Novelli MR, et al. Clinico-pathological features and p53 expression in left-sided sporadic colorectal cancers with and without microsatellite instability. J Pathol 1996, 179:370-375.
119. Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998, 42:673-679.
120. Jass JR Towards a molecular classification of colorectal cancer. Int J Colorectal Dis 1999, 14:194-200.
121. Chao A, Gilliland F, Willman C, et al. Patient and tumor characteristics of colon cancers with microsatellite instability: A population-based study. Cancer Epidemiol Biomarkers Prev 2000, 9:539-544.
122. Smyrk TC, Watson P, Kaul K, Lynch HT Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001, 91:2417-2422.
123. Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: Parallel pathways of tumorigenesis. Am J Pathol 2001, 159:2107-2116.
124. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77.
125. Halling KC, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999, 91:1295-1303.
126. Tuppurainen K, Mäkinen JM, Junttila O, et al. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol 2005, 207:285-294.
127. Loy TS, Kaplan PA Villous adenocarcinoma of the colon and rectum: A clinicopathologic study of 36 cases. Am J Surg Pathol 2004, 28:1460-1465.
128. Chung YF, Eu KW, Machin D, et al. Young age is not a poor prognostic marker in colorectal cancer. Br J Surg 1998, 85:1255-1259.
129. Cusack JC, Giacco GG, Cleary K, et al. Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma. J Am Coll Surg 1996, 183:105-112.
130. Griffin PM, Lift JM, Greenberg R, Clark WS Adenocarcinomas of the colon and rectum in persons under 40 years old: A population-based study. Gastroenterology 1991, 100:1033-1040.
131. Scott KW, Grace RH Detection of lymph node metastases in colorectal carcinoma before and after fat clearance. Br J Surg 1989, 76:1165-1167.
132. Wood TF, Tsioulias GJ, Morton DL, et al. Focused examination of sentinel lymph nodes upstages early colorectal carcinoma. Am Surg 2000, 66:998-1003.
133. Bertagnolli M, Miedema B, Redston M, et al. Sentinel node staging of resectable colon cancer: Results of a multicenter study. Ann Surg 2004, 240:624-628. discussion 628-630,.
134. Redston M, Compton CC, Miedema BW, et al. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: Results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol 2006, 24:878-883.
135. Tan J, Gurdip S, Greco MA, et al. Villin, cytokeratin 7, and cytokeratin 20 expression in pulmonary adenocarcinoma with ultrastructural evidence of microvilli with rootlets. Hum Pathol 1998, 29:390-396.
136. Werling RW, Yaziji H, Bacchi CE, Gown AM CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003, 27:303-310.
137. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004, 17:1392-1399.
138. Lewis MR, Deavers MT, Silva EG, Malpica A Ovarian involvement by metastatic colorectal adenocarcinoma: Still a diagnostic challenge. Am J Surg Pathol 2006, 30:177-184.
139. Chu P, Wu E, Weiss LM Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol 2000, 13:962-972.
140. Lee BH, Hecht JL, Pinkus JL, Pinkus GS WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002, 117:745-750.
141. Chen ZM, Wang HL Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. Am J Surg Pathol 2004, 28:1352-1359.
142. Tebbutt NC, Cattell E, Midgley R, et al. Systemic treatment of colorectal cancer. Eur J Cancer 2002, 38:1000-1015.
143. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007, 57:168-185.
144. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345:939-944.
145. Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994, 106:899-906.
146. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998, 16:295-300.
147. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. J Clin Oncol 1999, 17:1356-1363.
148. Wolmark N, Bryant J, Smith R, et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol C-05. J Natl Cancer Inst 1998, 90:1810-1816.
149. Henson DE, Fielding LP, Grignon DJ, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors: Summary. Members of the Cancer Committee. Arch Pathol Lab Med 1995, 119:1109-1112.
150. Compton CC Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol 2003, 16:376-388.
151. Dukes C The classification of cancer of the rectum. J Pathol Bacteriol 1932, 35:323-332.
152. Hermanek PH, Henson DE, Hutter RVP, Sobin LH TNM Supplement 1993, Springer-Verlag, New York.
153. Graham DM, Appelman HD Crohn's-like lymphoid reaction and colorectal carcinoma: A potential histologic prognosticator. Mod Pathol 1990, 3:332-335.
154. Shepherd NA, Baxter KJ, Love SB The prognostic importance of peritoneal involvement in colonic cancer: A prospective evaluation. Gastroenterology 1997, 112:1096-1102.
155. Galvis CO, Raab SS, D'Amico F, Grzybicki DM Pathologists' assistants practice: A measurement of performance. Am J Clin Pathol 2001, 116:816-822.
156. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001, 19:157-163.
157. Calaluce R, Miedema BW, Yesus YW Micrometastasis in colorectal carcinoma: A review. J Surg Oncol 1998, 67:194-202.
158. Oberg A, Stenling R, Tavelin B, Lindmark G Are lymph node micrometastases of any clinical significance in Dukes stages A and B colorectal cancer?. Dis Colon Rectum 1998, 41:1244-1249.
159. Quirke P, Durdey P, Dixon MF, Williams NS Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: Histopathological study of lateral tumour spread and surgical excision. Lancet 1986, 2:996-999.
160. Adam IJ, Mohamdee MO, Martin IG Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994, 344:707-711.
161. Heald RJ, Husband EM, Ryall RD The mesorectum in rectal cancer surgery: The clue to pelvic recurrence?. Br J Surg 1982, 69:613-616.
162. Macfarlane JK, Ryall RD, Heald RJ Mesorectal excision for rectal cancer. Lancet 1993, 341:457-460.
163. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
164. Reynolds JV, Joyce WP, Dolan J, et al. Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Br J Surg 1996, 83:1112-1115.
165. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: Not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002, 26:350-357.
166. Nagtegaal ID, van der Velde CJH, van der Worp E, et al. Macroscopic evaluation of rectal cancer resection specimen: Clinical significance of the pathologist in quality control. J Clin Oncol 2002, 20:1729-1734.
167. Chapuis PH, Dent OF, Fisher R, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985, 72:698-702.
168. Michelassi F, Block GE, Vannucci L, et al. A 5- to 21-year follow-up and analysis of 250 patients with rectal adenocarcinoma. Ann Surg 1988, 208:379-389.
169. Volk EE, Goldblum JR, Petras RE, et al. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995, 109:1801-1807.
170. Talbot IC, Ritchie S, Leighton M, et al. Invasion of veins by carcinoma of rectum: Method of detection, histological features and significance. Histopathology 1981, 5:141-163.
171. Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999, 189:487-495.
172. Jass JR Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986, 39:585-589.
173. Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: Results of multivariate analysis. Hum Pathol 1995, 26:31-38.
174. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: A population-based study. Gastroenterology 2007, 133:48-56.
175. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
176. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
177. Carlon CA, Fabris G, Arslan-Pagnini C, et al. Prognostic correlations of operable carcinoma of the rectum. Dis Colon Rectum 1985, 28:47-50.
178. Jass JR, Love SB, Northover JM A new prognostic classification of rectal cancer. Lancet 1987, 1:1303-1306.
179. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993, 36:627-635.
180. Prall F Tumour budding in colorectal carcinoma. Histopathology 2007, 50:151-162.
181. Ueno H, Murphy J, Jass JR, et al. Tumour "budding" as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002, 40:127-132.
182. Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: Tumor budding and cytoplasmic podia. Dis Colon Rectum 2006, 49:1422-1430.
183. Vermeulen PB, Van Den Eynden GG, Huget P, et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999, 79:316-322.
184. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000, 88:1739-1757.
185. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994, 331:213-221.
186. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206.
187. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996, 110:682-687.
188. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996, 335:1727-1732.
189. Houlston RS What we could do now: Molecular pathology of colorectal cancer. Mol Pathol 2001, 54:206-214.
190. Goh H-S, Chan C-S, Khine K, Smith DR p53 and behaviour of colorectal cancer. Lancet 1994, 344:233-234.
191. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997, 3:231-234.
192. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998, 90:675-684.
193. Aschele C, Lonardi S, Monfardini S Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002, 28:27-47.
194. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5?-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001, 7:2832-2839.
195. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
196. Bertagnolli MM, Compton CC, Niedzwiecki D, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol 2006, 24(18 Suppl):10003. (abstr),.
197. Magrini R, Bhonde MR, Hanski ML, et al. Cellular effects of CPT-11 on colon carcinoma cells: Dependence on p53 and hMLH1 status. Int J Cancer 2002, 101:23-31.
198. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 1998, 58:1149-1158.
199. McGill G, Fisher DE p53 and cancer therapy: A double-edged sword. J Clin Invest 1999, 104:223-225.
200. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and k-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
201. Minsky BD, Cohen AM, Kemeny M, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992, 10:79-84.
202. Minsky BD, Cohen AM, Kemeny M, et al. Combined modality therapy of rectal cancer: Decreased acute toxicity with the preoperative approach. J Clin Oncol 1992, 10:1218-1224.
203. Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: An analysis of 488 patients. J Am Coll Surg 2002, 194:131-135. discussion 135-136,.
204. Rullier A, Laurent C, Vendrely V, et al. Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma. Am J Surg Pathol 2005, 29:602-606.
205. Scheele J, Stangl R, Altendorf-Hofmann A Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg 1990, 77:1241-1246.
206. Stangl R, Altendorf-Hofmann A, Charley RM, et al. Factors influencing
207. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938-946.
208. Ruers T, Bleichrodt RP Treatment of liver metastases: An update on the possibilities and results. Eur J Cancer 2002, 38:1023-1033.
209. Elias D, Cavalcanti A, Sabourin JC, et al. Resection of liver metastases from colorectal cancer: The real impact of the surgical margin. Eur J Surg Oncol 1998, 24:174-179.
210. Lynch HT, Lynch JF What the physician needs to know about Lynch syndrome: An update. Oncology 2005, 19:455-463. discussion 463-464, 466, 469,.
211. Abdel-Rahman WM, Mecklin JP, Peltomaki P The genetics of HNPCC: Application to diagnosis and screening. Crit Rev Oncol Hematol 2006, 58:208-220.
212. Gruber SB New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology 2006, 130:577-587.
213. Vasen HF, Mecklin JP, Khan PM, Lynch HT The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-425.
214. Vasen HF, Watson P, Mecklin JP, Lynch HT New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999, 116:1453-1456.
215. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005, 352:1851-1860.
216. Lindor NM, Rabe K, Petersen G, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: Familial colorectal cancer type X. JAMA 2005, 293:1979-1985.
217. Jass JR Diagnosis of hereditary non-polyposis colorectal cancer. Histopathology 1998, 32:491-497.
218. Goel A, Arnold CN, Boland CR Multistep progression of colorectal cancer in the setting of microsatellite instability: New details and novel insights. Gastroenterology 2001, 121:1497-1502.
219. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
220. Redston M Carcinogenesis in the GI tract: From morphology to genetics and back again. Mod Pathol 2001, 14:236-245.
221. Felton KE, Gilchrist DM, Andrew SE Constitutive deficiency in DNA mismatch repair. Clin Genet 2007, 71:483-498.
222. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
223. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
224. Marcus VA, Madlensky L, Gryfe R, et al. Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol 1999, 23:1248-1255.
225. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002, 20:1043-1048.
226. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996, 56:4836-4840.
227. Lagerstedt Robinson K, Liu T, Vandrovcova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007, 99:291-299.
228. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
229. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
230. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793.
231. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007, 104:18654-18659.
232. Lynch HT, Coronel SM, Okimoto R, et al. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 2004, 291:718-724.
233. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 2006, 296:1507-1517.
234. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006, 296:1479-1487.
235. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006, 296:1469-1478.
236. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007, 44:353-362.
237. Jass JR Heredity and DNA methylation in colorectal cancer. Gut 2007, 56:154-155.
238. Oh K, Redston M, Odze RD Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon. Hum Pathol 2005, 36:101-111.
239. Greenson JK Dysplasia in inflammatory bowel disease. Semin Diagn Pathol 2002, 19:31-37.
240. Eaden JA, Mayberry JF Colorectal cancer complicating ulcerative colitis: A review. Am J Gastroenterol 2000, 95:2710-2719.
241. Harpaz N, Talbot IC Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol 1996, 13:339-357.
242. Jain SK, Peppercorn MA Inflammatory bowel disease and colon cancer: A review. Dig Dis 1997, 15:243-252.
243. Jayaram H, Satsangi J, Chapman RW Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: Fact or fiction?. Gut 2001, 48:430-434.
244. Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971, 285:17-21.
245. Ekbom A, Helmick C, Zack M, Adami HO Ulcerative colitis and colorectal cancer: A population-based study. N Engl J Med 1990, 323:1228-1233.
246. Benhattar J, Saraga E Molecular genetics of dysplasia in ulcerative colitis. Eur J Cancer 1995, 31A:1171-1173.
247. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992, 103:1611-1620.
248. Yin J, Harpaz N, Tong Y, et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993, 104:1633-1639.
249. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994, 107:369-378.
250. Fogt F, Vortmeyer AO, Goldman H, et al. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol 1998, 29:131-136.
251. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994, 54:3025-3033.
252. Rabinovitch PS, Dziadon A, Brentnall TA, et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 1999, 59:5148-5153.
253. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002, 32:280-284.
254. Watanabe T, Kobunai T, Toda E, et al. Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res 2007, 13:415-420.
255. Vieth M, Tannapfel A New pieces of the pathogenetic mosaic in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2006, 18:123-124.
256. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology 2007, 133:1099-1105. quiz 1340-1341,.
257. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 1983, 14:931-968.
258. Shelton AA, Lehman RE, Schrock TR, Welton ML Retrospective review of colorectal cancer in ulcerative colitis at a tertiary center. Arch Surg 1996, 131:806-810. discussion 810-811,.
259. Pohl C, Hombach A, Kruis W Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000, 47:57-70.
260. Lashner BA, Turner BC, Bostwick DG, et al. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 1990, 35:349-352.
261. Greenstein AJ, Slater G, Heimann TM, et al. A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg 1986, 203:123-128.
262. Ky A, Sohn N, Weinstein MA, Korelitz BI Carcinoma arising in anorectal fistulas of Crohn's disease. Dis Colon Rectum 1998, 41:992-996.
263. Sugita A, Greenstein AJ, Ribeiro MB, et al. Survival with colorectal cancer in ulcerative colitis: A study of 102 cases. Ann Surg 1993, 218:189-195.
264. Levi GS, Harpaz N Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease. Am J Surg Pathol 2006, 30:1022-1029.
265. Odze RD Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006, 35:533-552.
266. Nikias G, Eisner T, Katz S, et al. Crohn's disease and colorectal carcinoma: Rectal cancer complicating longstanding active perianal disease. Am J Gastroenterol 1995, 90:216-219.
267. Heimann TM, Oh SC, Martinelli G, et al. Colorectal carcinoma associated with ulcerative colitis: A study of prognostic indicators. Am J Surg 1992, 164:13-17.
268. Quirke P, Morris E Reporting colorectal cancer. Histopathology 2007, 50:103-112.
269. Kummar S, Fogarasi M, Canova A, et al. Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma. Br J Cancer 2002, 86:1884-1887.
270. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol 1996, 9:901-909.
271. Rullier A, Le Bail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 2000, 24:870-876.